PLC
ZNTL icon

Peapod Lane Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Peapod Lane Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$835K Sell
366,868
-81,993
-18% -$212K 0.68% 53
2025
Q4 		$606K Sell
448,861
-116,510
-21% -$170K 0.52% 56
2025
Q3 		$854K Buy
565,371
+6,158
+1% +$9.23K 0.76% 50
2025
Q2 		$649K Buy
559,213
+795
+0.1% +$1.05K 0.65% 49
2025
Q1 		$888K Buy
+558,418
New +$1.2M 1% 37

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Peapod Lane Capital's ZNTL Position: Q1 2026 in Review

Peapod Lane Capital reduced its Zentalis Pharmaceuticals (ZNTL) stake by 18% in Q1 2026, selling an estimated $212K and leaving 366,868 shares worth $835K. The position accounts for 0.68% of the portfolio, ranked #53.

Peapod Lane Capital first reported a position in ZNTL in Q1 2025 and has held it in 5 quarters since. The position peaked at $888K in Q1 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Peapod Lane Capital held 366,868 shares of Zentalis Pharmaceuticals worth $835K as of Q1 2026.
  • Peapod Lane Capital sold 81,993 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $212K.
  • Zentalis Pharmaceuticals made up 0.68% of Peapod Lane Capital's portfolio in Q1 2026, its #53 holding.
  • Peapod Lane Capital first reported a position in Zentalis Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Peapod Lane Capital's Zentalis Pharmaceuticals position peaked at $888K in Q1 2025.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Peapod Lane Capital's 13F filing for Q1 2026, filed 4 May 2026.